Trial reportClinical journal of the American Society of Nephrology : CJASN2012
Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00491322 (Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Oral vitamin DOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Pooled it
- Effects of vitamin D supplementation on FGF23: a randomized-controlled trial.European journal of nutrition · 2019Trial
- Effect of Cholecalciferol therapy on serum FGFJournal of endocrinological investigation · 2018Trial
- Trial
- Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial.The American journal of clinical nutrition · 2015Trial
- Nutritional vitamin D supplementation in dialysis: a randomized trial.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial.PloS one · 2014Trial
- High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.The American journal of clinical nutrition · 2012Trial
- 1,25-Dihydroxyvitamin D3 regulates furin-mediated FGF23 cleavage.JCI insight · 2023Article
- Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate.EFSA journal. European Food Safety Authority · 2023Article
- Effect of vitamin D supplementation on circulating fibroblast growth factor-23 concentration in adults with prediabetes.Aging clinical and experimental research · 2023Article
- Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020Observational
- Vitamin D deficiency is prevalent among idiopathic stone formers, but does correction pose any risk?Urolithiasis · 2017Article
- Acute Homeostatic Changes Following Vitamin DJournal of the Endocrine Society · 2017Article
- FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls.The Journal of clinical endocrinology and metabolism · 2017Article
- Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial.Therapeutics and clinical risk management · 2017Article
- Review
- FGF-23 and cardiovascular disease: review of literature.Current opinion in endocrinology, diabetes, and obesity · 2016Review
- A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia.Science signaling · 2016Article
- FGF23 in Acute and Chronic Illness.Disease markers · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesFibroblast growth factor 23 is a phosphate- and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 12-week trial conducted in a clinical research center, 18- to 45-year-old subjects (n=90) with 25-hydroxyvitamin D levels ≤20 ng/ml (by chemiluminescent immunoassay) were randomized to weekly ergocalciferol treatment of 50,000 international units or placebo, while consuming a self-selected diet. Changes in fibroblast growth factor 23, 25-hydroxyvitamin D (by liquid chromatography/tandem mass spectroscopy), 1,25-dihydroxyvitamin D, parathyroid hormone, and serum phosphate were measured.
resultsMean 25-hydroxyvitamin D (P<0.0001), 1,25-dihydroxyvitamin D (P=0.01), and fibroblast growth factor 23 (P=0.003) increased in the treatment versus placebo group. In the treatment group, 25-hydroxyvitamin D increased from 18 ± 7 to 40 ± 12 ng/ml at week 4 (P<0.0001) and remained stable at 43 ± 12 ng/ml at week 12 (P<0.0001); 1,25-dihydroxyvitamin D increased from 42 ± 17 to 52 ± 18 pg/ml at week 4 (P<0.001) and then remained stable, and fibroblast growth factor 23 increased from 43 ± 17 to 60 ± 33 pg/ml at week 8 (P=0.001) and 74 ± 42 pg/ml at week 12 (P<0.0001). Urinary phosphate excretion increased within the treatment group, but parathyroid hormone and serum phosphate were unchanged.
conclusionsErgocalciferol administration increases circulating fibroblast growth factor 23. When measuring fibroblast growth factor 23, concurrent 25-hydroxyvitamin D measurements should be obtained, because vitamin D deficiency may lower circulating fibroblast growth factor 23 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.